Validation builds for Regeneron’s IgG antibodies in allergy

With clinical validation in a second allergy indication, Regeneron could lead the charge into a new treatment paradigm for allergies with its IgG antibody platform.

On Saturday, the company shared Phase II proof-of-concept data showing its antibody cocktail for cat allergy, REGN-1908-1909, prevented early asthma reactions in response to allergen exposure during the three-month study. The data were presented at the virtual 2021 American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting. ...